Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: Major Depressive Disorder
In brief
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. Scopolamine infusions produced also a significant improvement in depression that was sustained over time. We therefore plan to investigate the feasibility and efficacy of open-label repeated intravenous administration of ketamine and scopolamine combined in this population of severely depressed, treatment-resistant patients. The results from this study could lead to the development of new strategies for the treatment of patients with TRD.
Key facts
- Study ID
- NCT01613820
- Run by
- Massachusetts General Hospital
- People needed
- 0
- Starts
- 2015-09-01
- Expected to finish
- 2017-02-01
- Last updated by the study team
- 2018-02-19
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Outpatients with sever treatment-resistant depression
- Currently depressed
- Currently under regular psychiatric care
- On an aggressive antidepressant regimen, stable for 4 weeks
You may not qualify if…
- No history of other major psychiatric illnesses, including bipolar disorder
- No history of psychosis
- No history of drug abuse
- No major medical illness or unstable medical condition.
Where it is running
- Depression Clinical and Reseach Program - MGH — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.